EA199900756A1 - Замещенные изохинолины в качестве нервно-мышечных блокаторов ультракраткосрочного действия - Google Patents

Замещенные изохинолины в качестве нервно-мышечных блокаторов ультракраткосрочного действия

Info

Publication number
EA199900756A1
EA199900756A1 EA199900756A EA199900756A EA199900756A1 EA 199900756 A1 EA199900756 A1 EA 199900756A1 EA 199900756 A EA199900756 A EA 199900756A EA 199900756 A EA199900756 A EA 199900756A EA 199900756 A1 EA199900756 A1 EA 199900756A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ultrastricated
isohenolins
nervous
substituted
action
Prior art date
Application number
EA199900756A
Other languages
English (en)
Other versions
EA002224B1 (ru
Inventor
Эрик Кливленд Бигхэм
Грейди Ивэн Бозуэлл
Джон Джозеф Сэйвэриз
Рой Арчибальд мл. Своринджен
Сэнджей Шешикент Пэйтел
Эрик Юджин Борос
Роберт Энтони мл. Мук
Винсент Сэймэно
Original Assignee
Глаксо Груп Лимитед
Корнелл Рисерч Фаундейшн, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9706117.0A external-priority patent/GB9706117D0/en
Priority claimed from GBGB9724987.4A external-priority patent/GB9724987D0/en
Application filed by Глаксо Груп Лимитед, Корнелл Рисерч Фаундейшн, Инк. filed Critical Глаксо Груп Лимитед
Publication of EA199900756A1 publication Critical patent/EA199900756A1/ru
Publication of EA002224B1 publication Critical patent/EA002224B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Вызывающие нервно-мышечную блокаду агенты сверхкраткосрочного действия формулы (I), которые полезны в качестве релаксантов скелетных мышц во время процедур экстренной интубации, обычной хирургии и в послеоперационных условиях, где X представляет собой галоген, h равно числу от 1 до 2, Y представляет собой водород или метокси, Zи Zпредставляют собой метил, Wи Wпредставляют собой углерод и A представляет собой фармацевтически приемлемый анион.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900756A 1997-03-25 1998-03-23 Замещенные изохинолины в качестве нервно-мышечных блокаторов ультракраткосрочного действия EA002224B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9706117.0A GB9706117D0 (en) 1997-03-25 1997-03-25 Ultra-short acting neuromuscular blockers
GBGB9724987.4A GB9724987D0 (en) 1997-11-27 1997-11-27 Ultra-short acting neuromuscular blockers
PCT/EP1998/001651 WO1998042674A1 (en) 1997-03-25 1998-03-23 Substituted isoquinolines as ultra short acting neuromuscular blockers

Publications (2)

Publication Number Publication Date
EA199900756A1 true EA199900756A1 (ru) 2000-08-28
EA002224B1 EA002224B1 (ru) 2002-02-28

Family

ID=26311255

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900756A EA002224B1 (ru) 1997-03-25 1998-03-23 Замещенные изохинолины в качестве нервно-мышечных блокаторов ультракраткосрочного действия

Country Status (37)

Country Link
US (2) US6177445B1 (ru)
EP (4) EP0975599B1 (ru)
JP (3) JP4112015B2 (ru)
KR (2) KR100554601B1 (ru)
CN (1) CN1203061C (ru)
AP (1) AP1797A (ru)
AR (1) AR012156A1 (ru)
AT (3) ATE430734T1 (ru)
AU (2) AU745382B2 (ru)
BR (1) BR9808422B1 (ru)
CA (1) CA2284802C (ru)
CO (1) CO4940499A1 (ru)
CZ (1) CZ293786B6 (ru)
DE (3) DE69840816D1 (ru)
DK (2) DK0975599T3 (ru)
EA (1) EA002224B1 (ru)
EE (1) EE04113B1 (ru)
ES (2) ES2242275T3 (ru)
HK (1) HK1023342A1 (ru)
HR (1) HRP980157B1 (ru)
HU (1) HU228230B1 (ru)
ID (1) ID22901A (ru)
IL (1) IL131918A (ru)
IS (2) IS2346B (ru)
MA (1) MA26476A1 (ru)
MY (1) MY121316A (ru)
NO (1) NO314726B1 (ru)
NZ (1) NZ337797A (ru)
PE (1) PE68399A1 (ru)
PL (1) PL190860B1 (ru)
PT (2) PT975599E (ru)
RS (1) RS49869B (ru)
SI (1) SI0975599T1 (ru)
TR (1) TR199902330T2 (ru)
TW (1) TW505635B (ru)
UY (1) UY24933A1 (ru)
WO (2) WO1998042675A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111662230A (zh) * 2019-03-06 2020-09-15 四川道珍科技有限公司 一类苄基异喹啉化合物、制备方法和用途

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100554601B1 (ko) * 1997-03-25 2006-03-03 아베라 파마슈티칼스, 인크. 초단기 작용성 신경근 차단제인 치환된 이소퀴놀린
US6911455B2 (en) * 1999-12-22 2005-06-28 Smithkline Beecham Corporation Methods for preparing pharmaceutical formulations
US6844904B2 (en) * 2002-12-07 2005-01-18 Cubic Corporation Fast PDLC device
WO2005041960A2 (en) * 2003-10-28 2005-05-12 Cornell Research Foundation, Inc. Neuromuscular blocking agents and antagonists thereof
JP5213137B2 (ja) 2006-12-06 2013-06-19 コーネル リサーチ ファウンデーション， インコーポレイテッド 中程度の持続時間の神経筋遮断剤およびそのアンタゴニスト
EP2125742A2 (en) * 2007-03-08 2009-12-02 Chemagis Ltd. (1r,1'r)-atracurium salts separation process
AU2008231470A1 (en) * 2007-03-26 2008-10-02 Chemagis Ltd. (1R,1'R)-atracurium salts separation process
WO2008132748A1 (en) 2007-05-01 2008-11-06 Chemagis Ltd. Process for producing cisatracurium compounds and associated intermediates
AU2008273724B2 (en) 2007-05-01 2013-05-23 Chemagis Ltd. Process for Producing Cisatracurium and Associated Intermediates
CA2687157A1 (en) * 2007-06-18 2008-12-24 Chemagis Ltd. (1r,1'r)-atracurium salts separation process
US20100256381A1 (en) * 2007-07-09 2010-10-07 Chemagis Ltd. Process for producing cisatracurium and associated intermediates
US8354537B2 (en) * 2007-10-29 2013-01-15 Chemagis Ltd. R,R1-atracurium salts
EP2283005A4 (en) * 2008-05-01 2011-08-31 Chemagis Ltd CISATRACURIUM DERIVATIVES, PREPARATION AND USES THEREOF
US8592451B2 (en) 2009-03-17 2013-11-26 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
US9220700B2 (en) 2009-08-19 2015-12-29 Cornell University Cysteine for physiological injection
WO2014005122A2 (en) * 2012-06-29 2014-01-03 Savarese John J Asymmetrical reversible neuromuscular blocking agents of ultra-short, short, or intermediate duration
CN103373959A (zh) * 2013-06-14 2013-10-30 安徽省先锋制药有限公司 顺式苄基异喹啉类化合物的制备方法及其用途
WO2014210369A2 (en) * 2013-06-28 2014-12-31 Cornell University Reversal of cysteine-inactivated neuromuscular blocking drugs with combinations of reversal agents
CN108375644B (zh) * 2016-12-07 2021-11-30 四川科瑞德制药股份有限公司 一种神经肌肉阻滞剂中间体的分析方法
CN108938573B (zh) * 2017-05-26 2021-08-10 四川科瑞德制药股份有限公司 一种神经肌肉阻滞剂组合物及其制备方法和用途
CN110776481B (zh) * 2018-07-24 2023-06-16 四川大学华西医院 一类双阳离子化合物及其制备方法和用途
CN109776486A (zh) * 2019-02-26 2019-05-21 武汉松石科技股份有限公司 一种硫酸亚丙酯的制备方法
CN110117297A (zh) * 2019-04-10 2019-08-13 珠海市赛纬电子材料股份有限公司 一种2-磷酸盐基硫酸丙烯酯的制备方法
TW202128628A (zh) * 2019-12-11 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 神經肌肉阻滯劑及其製備方法
CN111471013B (zh) * 2020-05-26 2021-04-30 朗天药业(湖北)有限公司 一种米库氯铵及其注射液的制备方法
CN111909089B (zh) * 2020-08-14 2023-04-14 广东嘉博制药有限公司 一种米库氯铵对照品的制备方法
CN114057642B (zh) * 2021-12-10 2023-03-28 广东嘉博制药有限公司 一种米库氯铵中间体的合成方法
CN115073373A (zh) * 2022-07-08 2022-09-20 广东嘉博制药有限公司 一种不对称合成（r）-5’-甲氧基劳丹素的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3004031A (en) 1958-07-03 1961-10-10 Allen & Hauburys Ltd Diquaternary salts of papaverino esters
AU506657B2 (en) * 1975-12-10 1980-01-17 Wellcome Foundation Limited, The Isoquinoline derivatives
BE869415A (fr) * 1977-08-01 1979-01-31 Massachusetts Gen Hospital Agents de blocage neuromusculaire
US4701460A (en) * 1980-12-17 1987-10-20 Burroughs Wellcome Co. Long duration neuromuscular blocking agents
JPS5899465A (ja) * 1981-11-23 1983-06-13 ザ・ウエルカム・フアウンデ−シヨン・リミテツド イソキノリン誘導体
GB8418303D0 (en) * 1984-07-18 1984-08-22 Wellcome Found Compounds
BG41897A1 (en) * 1985-07-19 1987-09-15 Ivanov Dichlormethylate of n, n'- 4, 10- dioxa- 3, 11- bis- tetrahydropapaverine and method for its preparation
GB9015473D0 (en) * 1990-07-13 1990-08-29 Wellcome Found Neuromuscular blocking agents
JPH04112016A (ja) * 1990-09-03 1992-04-14 Fuji Electric Co Ltd トランスファ成形金型用プランジャ及びトランスファ成形装置
US5240939A (en) * 1991-10-31 1993-08-31 Anaquest, Inc. Nitrogen bridge tetrahydroisoquinolines
KR100554601B1 (ko) * 1997-03-25 2006-03-03 아베라 파마슈티칼스, 인크. 초단기 작용성 신경근 차단제인 치환된 이소퀴놀린

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111662230A (zh) * 2019-03-06 2020-09-15 四川道珍科技有限公司 一类苄基异喹啉化合物、制备方法和用途

Also Published As

Publication number Publication date
US6187789B1 (en) 2001-02-13
ATE295351T1 (de) 2005-05-15
CA2284802C (en) 2009-06-16
AP9901658A0 (en) 1999-09-30
JP4112016B2 (ja) 2008-07-02
WO1998042674A1 (en) 1998-10-01
HK1023342A1 (en) 2000-09-08
AR012156A1 (es) 2000-09-27
DE69830157D1 (de) 2005-06-16
HUP0001556A2 (hu) 2001-04-28
KR20010005621A (ko) 2001-01-15
DE69830157T2 (de) 2006-05-11
ES2210757T3 (es) 2004-07-01
BR9808422A (pt) 2000-05-23
PL335885A1 (en) 2000-05-22
IL131918A (en) 2005-09-25
PL190860B1 (pl) 2006-02-28
PT971898E (pt) 2005-07-29
WO1998042675A1 (en) 1998-10-01
JP2002503220A (ja) 2002-01-29
HUP0001556A3 (en) 2002-01-28
KR100578443B1 (ko) 2006-05-11
AU745382B2 (en) 2002-03-21
EP1526130A1 (en) 2005-04-27
BR9808422B1 (pt) 2010-08-24
JP2002517168A (ja) 2002-06-11
ATE254107T1 (de) 2003-11-15
EP1380573A2 (en) 2004-01-14
EP0975599A1 (en) 2000-02-02
HRP980157A2 (en) 1999-02-28
EP1380573B1 (en) 2009-05-06
AP1797A (en) 2007-11-15
KR20050103984A (ko) 2005-11-01
DE69840816D1 (de) 2009-06-18
IS8717A (is) 2008-03-03
ID22901A (id) 1999-12-16
UY24933A1 (es) 2000-12-29
EP0971898B1 (en) 2005-05-11
MY121316A (en) 2006-01-28
CZ340499A3 (cs) 2000-04-12
YU48399A (sh) 2002-06-19
IS2346B (is) 2008-03-15
HU228230B1 (en) 2013-02-28
EP0971898A1 (en) 2000-01-19
CN1203061C (zh) 2005-05-25
JP2008019272A (ja) 2008-01-31
SI0975599T1 (en) 2004-04-30
TR199902330T2 (xx) 2000-02-21
EP1380573A3 (en) 2004-01-21
ES2242275T3 (es) 2005-11-01
NO314726B1 (no) 2003-05-12
MA26476A1 (fr) 2004-12-20
PE68399A1 (es) 1999-07-23
HRP980157B1 (en) 2004-10-31
KR100554601B1 (ko) 2006-03-03
NO994680L (no) 1999-11-24
CA2284802A1 (en) 1998-10-01
DK0975599T3 (da) 2004-03-15
IS5185A (is) 1999-09-17
NZ337797A (en) 2001-03-30
AU7521098A (en) 1998-10-20
EA002224B1 (ru) 2002-02-28
PT975599E (pt) 2004-03-31
DK0971898T3 (da) 2005-09-05
NO994680D0 (no) 1999-09-24
CO4940499A1 (es) 2000-07-24
JP4112015B2 (ja) 2008-07-02
CN1257483A (zh) 2000-06-21
US6177445B1 (en) 2001-01-23
ATE430734T1 (de) 2009-05-15
TW505635B (en) 2002-10-11
RS49869B (sr) 2008-08-07
EE9900424A (et) 2000-04-17
DE69819703D1 (de) 2003-12-18
AU6730598A (en) 1998-10-20
IL131918A0 (en) 2001-03-19
EP0975599B1 (en) 2003-11-12
DE69819703T2 (de) 2004-09-30
EE04113B1 (et) 2003-08-15
CZ293786B6 (cs) 2004-07-14

Similar Documents

Publication Publication Date Title
EA199900756A1 (ru) Замещенные изохинолины в качестве нервно-мышечных блокаторов ультракраткосрочного действия
LV5483A3 (lv) Izohinolinija atvasinajumu iegusanas panemiens
MX9701292A (es) Compuestos espiro-azabiciclicos utiles en la terapia.
SE9504661D0 (sv) New compounds
EP1428821A8 (en) Piperidin-4-yl amines with analgesic effect
EP0896533A4 (en) PENTAFLUOROBENZEN SULPHONAMIDES AND ANALOGS
AU5624699A (en) Use of 5ht-6 antagonists
YU20197A (sh) Analozi vitamina d3, farmaceutske kompozicije koje ih sadrže kao aktivnu materiju i njihova upotreba u proizvodnji farmaceutskih kompozicija
UA41355C2 (ru) Средство для лечения нейро-спида
DE69227583D1 (de) Arylmorpholine, herstellung und verwendung
UA41329C2 (ru) Фармацевтическая композиция для лечения нарушений сердечного ритма у крупных млекопитающих и людей, производные 3-фенилсульфонил-3,7-диазабицикло[3,3,1]нонана и лекарственное средство для лечения аритмии
BG103271A (en) Derivatives of n-(benzothiazol-2-yl) piperidine-1-ethaneamines, method for their preparation and application as therapeutical means
FR2597097B1 (fr) Derives de benzothiazepine-1, 5, leur preparation et leur application en therapeutique
DK0804186T3 (da) Indolditerpenalkaloidforbindelser
IL112344A (en) Pharmaceutical compositions comprising 7, 9, 9-trisubstituted- 3-benzoyl-3, 7-diazabicyclo £3.3.1| nonanes for the treatment of cardiac arrhythmias
RS50033B (sr) Derivati etansulfonil-piperidina
ES2096800T3 (es) Benzo(b)tiofen-3-il-piperazinas, un procedimiento para su preparacion y su uso como medicamentos.
EA199900684A1 (ru) Производные иминоазаантрациклинона для лечения амилоидоза
PH21982A (en) N-(3-triflouromethyl-phenyl)-n'-propargylpiperazine and method of use thereof
FI943875A (fi) 2,3,4,5-Tetrahydro-1H-3-bentsatsepiinejä ja niiden farmaseuttisesti hyväksyttäviä happoadditiosuoloja
CA1272214C (ru)
HUP0002727A2 (hu) Eljárás fibrinogén csökkentésére benzotiofénszármazékok felhasználásával
YU47750B (sh) Aktivni fluorosupstituisani benzimidazoli i postupci za njihovo dobijanje
BR9406996A (pt) Enanciômero processo para preparar o mesmo processo para ciclizar um composto e composto intermediário
EP0369696A3 (en) Quinolizine sulfonamides as antineoplastic agents

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU